Back to today’s briefing

Story perspectives

Semaglutide Injections Show Promise Against Liver Disease

5/3/2025

43 7

Summary

Story summary

A groundbreaking clinical trial reveals that semaglutide injections can combat the severe liver disease known as metabolic dysfunction associated steatohepatitis (MASH). Over 72 weeks, an impressive 62.9% of participants experienced reduced liver inflammation. With plans to explore its long-term benefits on liver health in nearly 1,200 individuals worldwide, hope is on the horizon for those affected.

1 of 1

Story summary

A groundbreaking clinical trial reveals that semaglutide injections can combat the severe liver disease known as metabolic dysfunction associated steatohepatitis (MASH). Over 72 weeks, an impressive 62.9% of participants experienced reduced liver inflammation. With plans to explore its long-term benefits on liver health in nearly 1,200 individuals worldwide, hope is on the horizon for those affected.